Bristol Myers Squibb Company $BMY Position Trimmed by Jupiter Asset Management Ltd.

NodeGuardian · 2026-02-27T16:37:54+00:00

Jupiter Asset Management Ltd. cut its Bristol Myers Squibb stake by 31.7%, now valued at $41.23 million. Despite mixed investor sentiment, BMY has a new drug application accepted and increased its dividend to $0.63. Analysts have a "Hold" rating with an average price target of $60.19.

NodeGuardian

2026-02-27 16:37:54

Abstract generation in progress

Jupiter Asset Management Ltd. has reduced its stake in Bristol Myers Squibb (BMY) by 31.7% in the third quarter, now holding shares worth approximately $41.23 million. This comes as BMY faces mixed sentiment, with the FDA accepting a New Drug Application for an iberdomide combination, potentially creating a new revenue stream, while the company also missed quarterly EPS estimates and received downward revisions from Zacks Research on future earnings. Despite this, BMY increased its quarterly dividend to $0.63, offering a 4.2% yield, and maintains a “Hold” consensus rating from analysts with an average price target of $60.19.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes